<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04004871</url>
  </required_header>
  <id_info>
    <org_study_id>GuangxiMUHK1</org_study_id>
    <nct_id>NCT04004871</nct_id>
  </id_info>
  <brief_title>Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma</brief_title>
  <official_title>The Efficacy and Safety of Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil, Concurrent Chemotherapy of Cisplatin and IMRT in Locoregionally Advanced Nasopharyngeal Carcinoma: A Prospective, Multi-centeric, Open, Non-controlled, Phase II Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Second affiliated hospital of Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guilin Medical University, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liuzhou Workers Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuzhou Red Cross Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guangxi Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nasopharyngeal carcinoma (NPC) is commonly observed in southern China, particularly in the&#xD;
      Pearl River delta area and the Xijiang River basin in the Guangdong and Guangxi provinces,&#xD;
      with an incidence rate as high as 25-50 per 100,000. The National Comprehensive Cancer&#xD;
      Network guidelines (version 1, 2018), have recommended use of induction chemotherapy followed&#xD;
      by CCRT as category 2A for NPC, especially the TPF regimen as category 1 for EBV-associated&#xD;
      disease. The nanoparticle albumin-bound paclitaxel (Nab-paclitaxel) is a promising new agent&#xD;
      with more efficient entry to the tumor microenvironment and preferential uptake by cancer&#xD;
      cells. Superior activity of Nab-paclitaxel regimens without the necessity for&#xD;
      antianaphylactic pretreatments has been shown in various solid tumors compared with the&#xD;
      traditional solvent-based paclitaxel-based ones. However, the safety and efficacy of&#xD;
      combination of Nab-paclitaxel, cisplatin and Fluorouracil (APF) has not been determined in&#xD;
      patients with locoregionally advanced NPC. In this prospective, Multi-centeric, Open,&#xD;
      Non-controlled phase II clinical trial, investigators perform an exploratory study to the&#xD;
      efficacy and Safety of APF.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 5, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>3 years</time_frame>
    <description>To be determined by measurement of target lesions according to RECIST criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Failure-free survival (FFS)</measure>
    <time_frame>3 years</time_frame>
    <description>From the date of registration to the date of either locally, regionally or distant failure or last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival（OS）</measure>
    <time_frame>3 years</time_frame>
    <description>From the date of registration to the date of death is observed or to last follow-up visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>3 years</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events Evaluated according to NCI-CTC AE V4.03</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <condition>Nasopharyngeal Cancer</condition>
  <condition>Nasopharynx Cancer</condition>
  <arm_group>
    <arm_group_label>Induction chemotherapy and concurrent chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive induction chemotherapy with Nab-paclitaxel, cisplatin and fluorouracil every three weeks for three cycles before radiotherapy, and then receive concurrent chemoradiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel, Cisplatin and Fluorouracil</intervention_name>
    <description>Patients receive Nab-paclitaxel (200mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before concurrent chemoradiotherapy.</description>
    <arm_group_label>Induction chemotherapy and concurrent chemoradiotherapy</arm_group_label>
    <other_name>APF induction chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>concurrent chemoradiotherapy</intervention_name>
    <description>Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.</description>
    <arm_group_label>Induction chemotherapy and concurrent chemoradiotherapy</arm_group_label>
    <other_name>Radical radiotherapy and concurrent cisplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with newly histologically confirmed non-keratinizing (according to World&#xD;
             Health Organization (WHO) histologically type).&#xD;
&#xD;
          2. Tumor staged as T3-4/N1-3 (according to the 8th UICC edition).&#xD;
&#xD;
          3. No evidence of distant metastasis (M0).&#xD;
&#xD;
          4. EBV positive.&#xD;
&#xD;
          5. Satisfactory performance status: ECOG≤2.&#xD;
&#xD;
          6. Adequate marrow: leucocyte count ≥4000/uL, hemoglobin ≥90g/L and platelet count&#xD;
             ≥100000/μL.&#xD;
&#xD;
          7. Normal liver function test: Alanine Aminotransferase (ALT)、Aspartate Aminotransferase&#xD;
             (AST) &lt;1.5×upper limit of normal (ULN) concomitant with alkaline phosphatase (ALP)&#xD;
             ≤2.5×ULN, and bilirubin ≤ULN.&#xD;
&#xD;
          8. Adequate renal function: creatinine clearance ≥60 ml/min.&#xD;
&#xD;
          9. Patients must be informed of the investigational nature of this study and give written&#xD;
             informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. WHO Type keratinizing squamous cell carcinoma or basaloid squamous cell carcinoma.&#xD;
&#xD;
          2. Age&gt;60 years or &lt;18 years.&#xD;
&#xD;
          3. Treatment with palliative intent.&#xD;
&#xD;
          4. Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in&#xD;
             situ cervical cancer.&#xD;
&#xD;
          5. Pregnancy or lactation.&#xD;
&#xD;
          6. History of previous radiotherapy (except for non-melanomatous skin cancers outside&#xD;
             intended RT treatment volume).&#xD;
&#xD;
          7. Prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes.&#xD;
&#xD;
          8. Any severe intercurrent disease, which may bring unacceptable risk or affect the&#xD;
             compliance of the trial, for example, unstable cardiac disease requiring treatment,&#xD;
             renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose&#xD;
             &gt;1.5×ULN), and emotional disturbance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kai Hu</last_name>
    <phone>+8613907710887</phone>
    <email>gxhukai@hotmail.com</email>
  </overall_contact>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 26, 2019</study_first_submitted>
  <study_first_submitted_qc>June 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2019</study_first_posted>
  <last_update_submitted>July 1, 2019</last_update_submitted>
  <last_update_submitted_qc>July 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangxi Medical University</investigator_affiliation>
    <investigator_full_name>Kai Hu</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

